Skip to main content
Figure 1 | BMC Veterinary Research

Figure 1

From: Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose

Figure 1

Toceranib plasma concentrations on day 30 of treatment. Shown are representative plasma toceranib concentrations from 4 dogs obtained on day 30 over 12 hours following drug administration. In this study, 28/40 dogs had Cmax at 6 or 8 hours on day 30. Two of the dogs shown experienced Cmax at 8 hours while the other two experienced Cmax after this time.

Back to article page

BMC Veterinary Research

ISSN: 1746-6148

Contact us